XTX Topco Ltd Buys 16,487 Shares of Fresenius Medical Care AG (NYSE:FMS)

XTX Topco Ltd boosted its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 70.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,769 shares of the company’s stock after buying an additional 16,487 shares during the quarter. XTX Topco Ltd’s holdings in Fresenius Medical Care were worth $847,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP grew its position in Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after buying an additional 581 shares during the period. GAMMA Investing LLC grew its position in Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after buying an additional 1,675 shares during the period. ORG Wealth Partners LLC bought a new position in Fresenius Medical Care during the third quarter valued at about $112,000. Venturi Wealth Management LLC grew its position in Fresenius Medical Care by 1,045.8% during the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after buying an additional 4,800 shares during the period. Finally, Signaturefd LLC grew its position in Fresenius Medical Care by 8.4% during the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after buying an additional 672 shares during the period. Institutional investors own 8.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on FMS. Berenberg Bank began coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective on the stock. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial upped their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. Finally, StockNews.com began coverage on shares of Fresenius Medical Care in a report on Thursday, November 28th. They set a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $24.30.

Fresenius Medical Care Trading Down 0.4 %

Shares of Fresenius Medical Care stock opened at $23.91 on Wednesday. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $24.31. The company has a market cap of $14.03 billion, a price-to-earnings ratio of 19.76, a PEG ratio of 0.98 and a beta of 0.93. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $21.29 and its 200-day moving average price is $20.39.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.